Presentation- Pursuit of Sustainable Healthcare through Personalized Medicine with HPC View the presentation by Biovista’s Graham Anthony at the HPC User Forum, Milwaukee 2017.
Author: Vassilis Virvilis
BioWorld: Biovista lands new backing for AI-driven personalized medicine ‘Prodigy’
Article By Michael Fitzhug, Staff Writer BioWorld, Monday, August 14, 2017 Drug repositioning specialist Biovista Inc. has tapped Hewlett Packard Enterprise Co. (HPE) to add greater computing power to Project Prodigy, a personalized medicine platform that leverages artificial intelligence (AI) to help doctors identify novel drugs for hard-to-treat patients. HPE, a spin-off of HP Inc. … Read More
Biovista expands Project Prodigy collaborations in personalized medicine
Biovista and Hewlett Packard Enterprise to collaborate on next generation AI and Big Data Analytics to advance real-world personalized medicine at community hospital settings. CHARLOTTESVILLE, Va., Aug. 10, 2017 /PRNewswire/ — Biovista announced today that it is collaborating with HPE to advance Biovista’s Project Prodigy Big Data AI healthcare platform applied in the personalized medicine … Read More
Sarah Bush Lincoln to Use Biovista’s Project Prodigy Artificial Intelligence Engine to Identify and Validate New Therapeutic Options for Further Research
Charlottesville, VA (PRWEB) January 19, 2017 Sarah Bush Lincoln (SBL), a hospital and health care organization that is home to more than 300,000 provider office visits per year, and Biovista announced today that they will be working together to validate novel therapeutic options generated in the real-world practice of a hospital and health center, using … Read More
Biovista announces strong preclinical results for two drugs targeting Niemann-Pick Disease Type A
CHARLOTTESVILLE, Va. – Jan. 12, 2017 – Biovista Inc. today announced that two drugs targeting Niemann-Pick Disease Type A (NPA), have shown strong positive results in the Acid Sphingomyelinase ASM knock-out (ASMKO) mouse model. Both repositioning candidates (BVA-901A and BVA-901B) tested by the laboratory of Dr. M.D. Ledesma at the Madrid Center for Molecular Biology … Read More